Company Overview and News

24
Prospect Capital's Dividend And NAV Sustainability Analysis - Part 2 (Including September-October 2018 Dividend Projection)

13h seekingalpha
Part 2 of this article discusses two topics/trends impacting PSEC’s future dividend and NAV sustainability (forward-looking metrics).
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ ARU OCSI MSCA.CL OCSL MCX TRI NEWTL PBB

0
Gladstone Investment Corporation Announces Proxy Filing and Conference Call Date to Discuss Proxy Proposals

2018-06-15 globenewswire
MCLEAN, Va., June 15, 2018 (GLOBE NEWSWIRE) -- Gladstone Investment Corporation (NASDAQ:GAIN) (the "Company") announced today that it plans to hold a conference call on Tuesday, June 26, 2018, at 9:00 am EDT to discuss the matters scheduled for a vote at this year's annual meeting of stockholders to be held on August 2, 2018. On Friday, June 15, 2018, the Company filed its proxy statement for the annual meeting of stockholders (the "Proxy Statement") with the U.
GAIN GAINM GADDP

25
TPG Specialty Lending's NAV Sustainability And Investment Rating Analysis (Post Q1 2018 Earnings)

2018-06-14 seekingalpha
Following continued requests from readers, this article first performs a FMV investing rating analysis on TSLX’s portfolio companies over the prior four quarters.
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC RXNRP REXXQ MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX REXX JIVE NEWTL PBB

23
Main Street Capital's NAV, Dividend, And Valuation Compared To 14 BDC Peers (Post Q1 2018 Earnings) - Part 2

2018-06-12 seekingalpha
This article compares MAIN’s recent dividend per share rates, yield percentages, and several other dividend sustainability metrics to fourteen other BDC peers.
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX NEWTL PBB

25
TPG Specialty Lending's Dividend Sustainability Analysis (Includes Q3-Q4 2018 Dividend Projection)

2018-06-07 seekingalpha
Following multiple requests by readers, this article analyzes TSLX’s dividend sustainability by performing three tests based on historical and projected future quarterly results.
AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC RXNRP REXXQ MSCA TSLX NEWT SLRA MCC ARCC FSIC MAIN AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX REXX NEWTL PBB

0
Gladstone Investment Corporation Exits its Investment in Drew Foam Companies, Inc.

2018-06-04 globenewswire
MCLEAN, Va., June 04, 2018 (GLOBE NEWSWIRE) -- Gladstone Investment Corporation (NASDAQ:GAIN) (“Gladstone Investment”) announced today the sale of its equity interest and the prepayment of its debt investments in Drew Foam Companies, Inc. (“Drew Foam”) to a private equity firm. As a result of this transaction, Gladstone Investment realized a significant gain on its equity investment.
GAIN GAINM GADDP

23
Gladstone  Investment's Dividend Sustainability Analysis (Includes July-December 2018 Dividend Projection)

2018-06-01 seekingalpha
Following multiple requests, this article analyzes GAIN’s dividend sustainability by performing three tests based on historical and projected future quarterly results.
AIY AINV GAIN MCQ GAINM MCV OSLE GADDP MSCA TSLX NEWT MCC ARCC FSIC MAIN AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX NEWTL PBB

1
Gladstone Investment's (GAIN) CEO David Gladstone on Q4 2017 Results - Earnings Call Transcript

2018-05-16 seekingalpha
Good day, ladies and gentlemen, and welcome to the Gladstone Investment Corporation Fourth Quarter and Year Ended 03/31/2018 Earnings Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] And as a reminder, this conference call is being recorded.
GAIN GAINM GADDP

26
Assessing Main Street Capital's Results For Q1 2018 (Includes Investment Rating Analysis)

2018-05-09 seekingalpha
This article assesses MAIN’s performance for Q1 2018 and compares results over the trailing twelve months.
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX CVOVQ CVO NEWTL PBB

0
Gladstone Investment Corporation and Bassett Creek Capital form the Bassett Creek Restoration Platform and Acquire J.R. Johnson

2018-05-01 globenewswire
MCLEAN, Va., May 01, 2018 (GLOBE NEWSWIRE) -- Gladstone Investment Corporation (NASDAQ:GAIN) (“Gladstone Investment”) announced today that on April 4, 2018, Gladstone Investment partnered with Bassett Creek Capital, Inc. (“BCC”) to form Bassett Creek Restoration, Inc. (“Bassett Creek Restoration”), a platform for acquiring and integrating restoration and renovation companies across the United States.
GAIN GAINM GADDP

0
You Won't Regret Adding This BDC

2018-05-01 seekingalpha
Unlike most BDCs, Gladstone has managed to significantly increase book value per share through consistent investment gains on its equities portfolio.
GAIN GAINM GADDP

22
Prospect Capital's Fiscal Q3 2018 NII And NAV Projection (How Much Of A Decrease?)

2018-04-27 seekingalpha
I am projecting PSEC will report a minor decrease in NAV for the 3/31/2018 quarter. I am also projecting PSEC will report a lower quarterly NII versus last quarter.
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ ARU OCSI MSCA.CL OCSL MCX NEWTL PBB

0
Gladstone Investment Corporation Announces Fourth Quarter and Year End Earnings Release and Conference Call Dates

2018-04-25 globenewswire
MCLEAN, Va., April 25, 2018 (GLOBE NEWSWIRE) -- Gladstone Investment Corporation (NASDAQ:GAIN) (the “Company”) announced today that it plans to report earnings for the fourth quarter and year ended March 31, 2018 after the stock market closes on Tuesday, May 15, 2018. The Company will hold a conference call on Wednesday, May 16, 2018, at 8:30 a.m. EDT to discuss its earnings results. Please call (855) 376-7516 to enter the conference call.
GAIN GAINM GADDP

0
Wait For A Drop Before Buying This 7.4%-Yielding, Monthly-Paying BDC

2018-04-22 seekingalpha
Gladstone Investment Corp. (GAIN) is an interesting BDC income vehicle, but shares now sell for a premium to net asset value. Gladstone Investment Corp. has a rate-sensitive balance sheet and about covered its dividend payout with net investment income, on average, in the last ten quarters. I think investors may want to wait for a drop before gobbling up shares for an income portfolio. An investment in Gladstone Investment Corp.
GAIN GAINM GADDP

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...